Allison Bratzel
Stock Analyst at Piper Sandler
(4.59)
# 232
Out of 5,147 analysts
58
Total ratings
65.22%
Success rate
21.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $87 → $100 | $81.15 | +23.23% | 5 | Feb 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $29.79 | +27.56% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $61.73 | +36.08% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $101.27 | +8.62% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.31 | +205.34% | 2 | Feb 6, 2026 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $14 | $7.65 | +83.01% | 3 | Feb 5, 2026 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $3 → $4 | $2.11 | +89.57% | 1 | Feb 5, 2026 | |
| IOBT IO Biotech | Downgrades: Neutral | $3 → $0.5 | $0.35 | +43.27% | 2 | Jan 26, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $33 → $42 | $33.31 | +26.09% | 2 | Jan 23, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $7.56 | +296.83% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $766.92 | +21.26% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $51 | $44.27 | +15.20% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $121.28 | -7.65% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $23.39 | +391.66% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $10.11 | +157.17% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $34.74 | -33.79% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $28.94 | -23.98% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.12 | +258.74% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $6.21 | +222.06% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.61 | +454.02% | 1 | Oct 13, 2023 |
Ionis Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $87 → $100
Current: $81.15
Upside: +23.23%
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $29.79
Upside: +27.56%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $61.73
Upside: +36.08%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $101.27
Upside: +8.62%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.31
Upside: +205.34%
Replimune Group
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $7.65
Upside: +83.01%
ALX Oncology Holdings
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.11
Upside: +89.57%
IO Biotech
Jan 26, 2026
Downgrades: Neutral
Price Target: $3 → $0.5
Current: $0.35
Upside: +43.27%
Tyra Biosciences
Jan 23, 2026
Maintains: Overweight
Price Target: $33 → $42
Current: $33.31
Upside: +26.09%
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $7.56
Upside: +296.83%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $766.92
Upside: +21.26%
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $44.27
Upside: +15.20%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $121.28
Upside: -7.65%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $23.39
Upside: +391.66%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $10.11
Upside: +157.17%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $34.74
Upside: -33.79%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $28.94
Upside: -23.98%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.12
Upside: +258.74%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $6.21
Upside: +222.06%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.61
Upside: +454.02%